Skip to main content

Site notifications

TGA grants provisional determination to Roche Products Pty Ltd combination COVID-19 treatment casirivimab + imdevimab (RONAPREVE)

On 20 August 2021 the TGA granted provisional determination to Roche Products Pty Ltd in relation to the combination therapy casirivimab + imdevimab (RONAPREVE)
Published

Related content

Help us improve the Therapeutic Goods Administration site